Townsend Richard Nolan 4

What Happened
Richard Nolan, CEO of Lexeo Therapeutics (LXEO), was awarded a total of 808,330 restricted stock units (RSUs) via two grant entries on Feb 4, 2026: 161,665 RSUs (reported as Acquired) and 646,665 RSUs (reported as a derivative acquisition). The filing reports a per-share price of $0.00 (awards/compensation, no cash exchanged) and a reported total value of $0.00. This is a compensation grant (not an open-market purchase or sale).

Key Details

• Transaction date(s): Feb 4, 2026; Form 4 filed Feb 6, 2026 (appears timely).
• Reported amounts: 161,665 RSUs (A) and 646,665 RSUs (A, derivative) — total 808,330 RSUs as reported. Price: $0.00 per share (award).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes of note:
  • F1: These are RSUs — each converts to one share when vested. Vesting: 25% on Feb 15, 2027, then 1/16th of the RSUs vest quarterly thereafter, subject to continued service.
  • F2: The filing notes it "includes 290,022 RSUs" (as described in the filing).
  • F3: Separately describes an option vesting schedule (25% on Feb 4, 2027, then 1/48th monthly thereafter).
• Transaction code: A = Award/Grant; the derivative flag on the larger grant indicates RSUs (contingent rights to shares), not an option exercise or sale.

Context
RSUs are compensation that convert into common shares only as they vest; they do not represent an immediate market purchase or sale. Because these are grants tied to future vesting, they reflect executive compensation/retention arrangements rather than a direct market signal. There is no indication in this filing that any shares were sold or that a cashless exercise occurred.